0.00
—
Close of 4 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Amarantus Bioscience Holdings
Its shares trade under the ticker AMBS. It has been listed since 29 September 2008. In the fiscal year to 31 December 2022, it reported revenue of $95,331 and a net loss of $4.8m. At that date it held total assets of $10.2m and shareholders' equity of −$24.7m.
Amarantus BioScience Holdings, Inc. is a biopharmaceutical company. The company is headquartered in San Francisco, California. The company went IPO on 2008-09-29. The firm has approximately three operating divisions: the diagnostics division, the therapeutics division and the drug discovery division. The company owns licenses to various product candidates in the therapeutic and diagnostic sectors of the life sciences industry. The company is developing diagnostic product candidates in the field of neurology, and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company, through its subsidiary, Cutanogen Corporation, is developing a regenerative medicine cell therapy-based autologous skin replacement product, Engineered Skin substitute, which is in mid-stage clinical development, for the treatment of life-threatening severe burns. The company is also developing a mid-stage clinical-stage pharmaceutical drug candidate, Eltoprazine, a small molecule 5HT1a/1b partial agonist for the treatment of symptomatic neurological disorders.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Sept 2008
- Employees
- 10
- Website
- amarantus.com ↗
Leadership
Pay as last reported
- Mr. Gerald CommissiongPresident, Chief Executive Officer, Director, since 2011$230,252
- Mr. Barney MonteChief Financial Officer, Interim Chief Operating Officer
- Dr. John CommissiongChief Scientific Officer, Director, since 2008$491,494
- Mr. Marc FaerberVice President - Operations, Controller, Treasurer, Secretary$163,343
- Mr. Conn FlaniganDirector
- Mr. Steven SpenceDirector
- Mr. Robert HarrisIndependent Director
- Mr. Donald HuffmanIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Amarantus Bioscience Holdings Inc possesses an innovative range of products that set it apart from competitors. The company's unique offerings give it a competitive edge in the market.
- Amarantus Bioscience Holdings Inc heavily invests in research and development activities, allowing them to continuously improve their products and stay ahead of industry trends. Their strong R&D capabilities enable them to develop groundbreaking solutions.
- With years of experience and a well-established market presence, Amarantus Bioscience Holdings Inc has built a reputation for delivering high-quality products and services. Their brand recognition and customer loyalty provide a solid foundation for growth.
Weaknesses
- Amarantus Bioscience Holdings Inc relies heavily on strategic partnerships with other organizations for various aspects of their business. Any negative changes in these partnerships could have a detrimental impact on the company's operations.
- The company faces financial constraints in terms of available resources. Limited funds may restrict their ability to expand operations, invest in new technologies, or pursue aggressive marketing strategies.
- As a biotechnology company, Amarantus Bioscience Holdings Inc operates in an industry that is heavily regulated. Changes in regulatory policies or compliance requirements can significantly affect their operations and product development.
Opportunities
- The increasing demand for biotechnology advancements presents an opportunity for Amarantus Bioscience Holdings Inc to expand its market presence. With their innovative products, the company can effectively capitalize on this growing demand.
- Forming strategic collaborations with other industry players can provide Amarantus Bioscience Holdings Inc with access to additional resources, expertise, and market opportunities. Such partnerships can further enhance their competitive advantage.
- Exploring and expanding into emerging markets with a rising focus on biotechnology creates opportunities for Amarantus Bioscience Holdings Inc to reach new customers and drive revenue growth.
Threats
- The biotechnology industry is highly competitive, with numerous players vying for market share. Amarantus Bioscience Holdings Inc faces the risk of increased competition, which may impact their market position and profitability.
- Fluctuations in the global economy can pose challenges to Amarantus Bioscience Holdings Inc. Economic uncertainty, market volatility, and reduced healthcare expenditure by consumers or governments could potentially affect the demand for their products.
- The biotechnology industry operates under strict regulations, requiring compliance with safety, ethical, and legal standards. Adapting to evolving regulations and obtaining necessary approvals can be time-consuming and costly for Amarantus Bioscience Holdings Inc.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.